Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) closed at $12.29 in the last session, up 4.42% from day before closing price of $11.77. In other words, the price has increased by $4.42 from its previous closing price. On the day, 1.09 million shares were traded. PHAT stock price reached its highest trading level at $12.49 during the session, while it also had its lowest trading level at $11.78.
Ratios:
We take a closer look at PHAT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.35 and its Current Ratio is at 2.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 14, 2025, initiated with a Overweight rating and assigned the stock a target price of $23.
On May 03, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $24.
Needham reiterated its Buy rating for the stock on January 05, 2024, while the target price for the stock was revised from $23 to $26.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 05 ’25 when Breedlove Robert Charles sold 461 shares for $12.09 per share. The transaction valued at 5,573 led to the insider holds 47,931 shares of the business.
Breedlove Robert Charles sold 1,692 shares of PHAT for $14,152 on Jul 16 ’25. The Principal Accounting Officer now owns 48,392 shares after completing the transaction at $8.36 per share. On May 21 ’25, another insider, Topper James N, who serves as the Director of the company, bought 3,780 shares for $3.86 each. As a result, the insider paid 14,609 and bolstered with 59,403 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PHAT now has a Market Capitalization of 873380992 and an Enterprise Value of 1296823936. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.65. Its current Enterprise Value per Revenue stands at 11.372 whereas that against EBITDA is -4.834.
Stock Price History:
The Beta on a monthly basis for PHAT is 0.44, which has changed by -0.35151517 over the last 52 weeks, in comparison to a change of 0.17342639 over the same period for the S&P500. Over the past 52 weeks, PHAT has reached a high of $19.50, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 13.32%, while the 200-Day Moving Average is calculated to be 65.71%.
Shares Statistics:
According to the various share statistics, PHAT traded on average about 1.10M shares per day over the past 3-months and 1281900 shares per day over the past 10 days. A total of 70.10M shares are outstanding, with a floating share count of 39.63M. Insiders hold about 44.14% of the company’s shares, while institutions hold 46.68% stake in the company. Shares short for PHAT as of 1757894400 were 13999721 with a Short Ratio of 12.72, compared to 1755216000 on 12093175. Therefore, it implies a Short% of Shares Outstanding of 13999721 and a Short% of Float of 32.580003000000005.
Earnings Estimates
Phathom Pharmaceuticals Inc (PHAT) is currently under the scrutiny of 4.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.17 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$2.3 and -$3.49 for the fiscal current year, implying an average EPS of -$2.67. EPS for the following year is -$0.11, with 4.0 analysts recommending between $0.93 and -$1.17.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $47.03M. It ranges from a high estimate of $49.38M to a low estimate of $45.4M. As of. The current estimate, Phathom Pharmaceuticals Inc’s year-ago sales were $16.35MFor the next quarter, 8 analysts are estimating revenue of $54.92M. There is a high estimate of $57.5M for the next quarter, whereas the lowest estimate is $51M.
A total of 8 analysts have provided revenue estimates for PHAT’s current fiscal year. The highest revenue estimate was $173.47M, while the lowest revenue estimate was $165M, resulting in an average revenue estimate of $169.99M. In the same quarter a year ago, actual revenue was $55.25MBased on 7 analysts’ estimates, the company’s revenue will be $323.63M in the next fiscal year. The high estimate is $359.47M and the low estimate is $280M.
